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Hepatic cirrhosis is commonly associated with hyperestrogenism. Previous studies have reported morpho-
logic changes in benign and malignant prostate tissue exposed to estrogen or anti-androgens. To our
knowledge, histopathologic features of prostatic adenocarcinoma in patients with cirrhosis have not been
well-reported. We present a case of incidental, but pathologically signiﬁcant, prostatic adenocarcinoma
detected on autopsy in a 67-year-oldmale patientwith cirrhosis and spider angiomata. Themorphologic and
immunohistochemical features (including variable ERG expression) of the prostatic adenocarcinoma
were consistent with hormone exposure related changes, suggesting that cirrhosis-induced elevated
estrogen-to-testosterone ratio and exogenous hormone therapy might induce similar phenotypes.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hepatic cirrhosis is known to be associated with hyper-
estrogenism; manifestations in males include testicular atrophy,
gynecomastia, and decreased libido. Schenken et al described
nuclear size reduction, loss of nucleoli, chromatin condensation,
nuclear pyknosis, and cytoplasmic vacuolization in prostatic
adenocarcinoma after estrogen treatment.1 Subsequent studies
demonstrated these features as well as reduced mitotic activity in
prostatic adenocarcinoma, in addition to squamous metaplasia and
basal cell hyperplasia in background benign prostate glands.a patent on the detection of
.A.T., and A.M.C. are listed as
the diagnostic ﬁeld of use to
ed some rights to Ventana
has received honoraria from
ltant for Gen-Probe, Inc. and
isclosures.
niversity of Michigan Health
e, Ann Arbor, MI 48109, USA.
).
Inc. This is an open access article uAnti-androgen therapy has been reported to cause similar changes
in prostatic adenocarcinoma, and the malignant prostate glands
may be largely degenerated, leaving cleft-like spaces with irregular
acid mucinous pools and rare carcinoma cells.2 Importantly, pros-
tatic adenocarcinoma shows variable response to hormone expo-
sure, both within a tumor and between tumors from different
patients.
Barr and Sommers reviewed 100 autopsied cases of hepatic
cirrhosis and found changes indicative of estrogen effect (squamous
metaplasia and/or atrophy) more frequently in prostate tissues of
patients with cirrhosis than in controls.3 The morphology of the
identiﬁed cancers was not described. The degree of estrogenic effect
seen in the prostates of the majority of cirrhotic patients was
comparable to that seenwith stilbestrol therapy for prostatic cancer.
This report provides the autopsy, clinicopathologic, immuno-
histochemical and ﬂuorescence in situ hybridization (FISH)
description of an incidental, but pathologically signiﬁcant, prostatic
adenocarcinoma identiﬁed in a fatal case of cirrhosis.
Case presentation
Our patient was a 67-year-old man with history of cirrhosis
secondary to autoimmune hepatitis and one month of progressivender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Histologic features of benign and malignant prostate tissue at the time of autopsy in a patient with cirrhosis. (A) Benign prostate glands demonstrating a prominent basal
cell layer (H&E, 100 with scale bar 200 microns), (B) prostatic adenocarcinoma demonstrating small glands with atrophic features (H&E, 200 with scale bar 100 microns),
(C) prostatic adenocarcinoma with relatively small and pyknotic nuclei inﬁltrating around a residual benign prostatic gland (toward top of the image, H&E, 200 with scale bar 100
microns), (D) PIN4 immunohistochemistry demonstrates loss of basal cell marker expression in the prostatic adenocarcinoma with retained expression in the single benign gland
toward top of the image (H&E, 200 with scale bar 100 microns), (E) prostatic adenocarcinoma cells resembling histiocytes with small nuclei, indistinct nucleoli, and vacuolated
cytoplasm (H&E, 400 with scale bar 50 microns), (F) cleft-like spaces ﬁlled with mucin and rare carcinoma cells (H&E, 200 with scale bar 100 microns), (GeH) prostatic
adenocarcinoma adjacent to metastatic poorly differentiated hepatocellular carcinoma within a lymphovascular space (H&E, 100 with scale bar 200 microns, and H&E, 200 with
scale bar 100 microns, respectively).
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S.L. Skala et al. / Urology Case Reports 9 (2016) 37e40 39dyspnea, transferred to our hospital for liver transplant evaluation
in the setting of possible hepatorenal syndrome. Chest CT showed
ground-glass opacities concerning for infection, and broad-
spectrum antibiotics including coverage for Pneumocystis jiroveci
were started. His decline continued with development of refractory
lactic acidosis and acute kidney injury, so he was transitioned to
comfort care. He was pronounced dead ﬁve days after admission.
He had no known personal or family history of cancer.
Antemortem work-up included serum alpha fetoprotein and
prostate-speciﬁc antigen (PSA), which were within the reference
ranges, as well as abdominal ultrasound which demonstrated
cirrhosis with no deﬁnitive mass lesion. The autopsy revealed that
the cause of death was complications of widely metastatic poorly
differentiated hepatocellular carcinoma, including type B lactic
acidosis. An incidental prostatic adenocarcinoma (1.5 cm) with
invasion into periprostatic fat (pT3a) was also seen.
Microscopically, focal areas of the prostatic tumor showed both
well- and poorly formed glands with cells demonstrating nucleo-
lomegaly characteristic of prostatic adenocarcinoma. The majority
of the prostatic adenocarcinoma, however, demonstrated areas
with atrophic features, mucinous pools with absent-to-rare carci-
noma cells (reminiscent of acellular clefts), and tumor cells with
vacuolated cytoplasm and small nuclei with inconspicuous
nucleoli, resembling histiocytes (Fig. 1). The background benign
prostatic tissue showed a prominent basal cell layer with foci of
basal cell hyperplasia. Metastatic hepatocellular carcinomawas also
identiﬁed within the lymphovascular spaces in the prostate gland
(Fig. 1).
Immunohistochemical staining conﬁrmed diffuse PSA and PSMA
expression in the prostate cancer cells, which were as expected
negative for basal cell marker (p63 and CK34BE12) expression.Figure 2. Immunohistochemical and ﬂuorescence in situ hybridization analysis of prostat
(200 with scale bar 100 microns), (B) variable AR expression (H&E, 200 with scale bar 1
(D) The tumor was diffusely positive for ERG rearrangement by FISH at the genomic level. D
ERG allele ¼ yellow signal (colocalized signals), and rearranged ERG allele with loss of theFocal AMACR and variable (absent to moderate nuclear) androgen
receptor expression were present. ERG expression, which when
positive in our series of untreated patients is diffusely strong,4 was
variable in this case (from absent to strong) as has previously been
described in the context of anti-androgen therapy. Assessment of
TMPRSS2:ERG gene fusion using an interphase FISH assay (following
previous protocol4) conﬁrmed that this tumor was diffusely posi-
tive for ERG rearrangement at the genomic level through a deletion
mechanism (Fig. 2).
There was no reported exogenous hormone intake or exposure,
and hence, based on the clinical presentation of hepatic cirrhosis
and associated hyperestrogenism-induced stigmata like spider
angiomata, we attributed the morphological changes seen in this
prostatic adenocarcinoma to cirrhosis-induced hormonal imbal-
ance. By convention, this cancer was not assigned a Gleason score
due to the hormone exposure related changes.
Discussion
It is well-established that hepatic cirrhosis is associated with an
elevated estrogen-to-testosterone ratio linked to a spectrum of
clinical stigmata.3 To our knowledge, histologic features of prostatic
adenocarcinoma in patients with hepatic cirrhosis have not been
well-reported.
Herein, we report the presence of a pathologically signiﬁcant
prostatic adenocarcinoma (stage pT3a) identiﬁed in a patient with
cirrhosis and normal serum PSA. The majority of the prostatic
adenocarcinoma demonstrated features that have been described
in the context of exogenous estrogen or anti-androgen therapy,
including (1) nuclear size reduction, inconspicuous nucleoli, and
cytoplasmic vacuolization and (2) cleft-like spaces with mucinousic adenocarcinoma. (A) Tumor cells show diffuse moderate-to-strong PSA expression
00 microns), and (C) variable ERG expression (H&E, 200 with scale bar 100 microns).
ual-color, break apart FISH method to determine ERG rearrangement status: wild type
50 ERG (red) probe ¼ single green signal.
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seen in the background benign prostatic glands; however, benign
glands demonstrated basal cell hyperplasia, which is sometimes
associated with estrogen exposure.
TMPRSS2-ERG is an ETS gene fusion speciﬁc to neoplastic pros-
tate that occurs in more than 40% of localized and metastatic
prostate cancers in PSA-screened Caucasian cohorts.5 ERG immu-
nohistochemistry is less sensitive for detection of ERG rearrange-
ments in tumors that have been treatedwith hormone therapy than
in untreated tumors, presumably due to dysregulation of androgen
receptor signaling. This patient’s prostatic adenocarcinoma
demonstrated an ERG rearrangement at the genomic level and
variable (absent to strong) ERG protein expression, akin towhat has
been previously documented in patients with therapy-related
changes.4
Although this patient did not receive exogenous hormone
therapy, the histologic and immunohistochemical characteristics of
his prostate cancer are similar to those seen with estrogen or anti-
androgen therapy. Because there was no known indication for
testing, the patient’s sex hormone levels are unknown. Spider
angiomata, which are known stigmata of cirrhosis-induced hor-
monal imbalance, were present on his face and chest. Overall, these
ﬁndings indicate that the phenotypic features seen within this
patient’s prostatic adenocarcinoma are related to his underlying
cirrhosis-associated hormonal imbalance.The possibility of development of prostatic adenocarcinoma
with hormone exposure related changes in a patient with cirrhosis
has important implications for understanding prostate cancer
tumorigenesis in these patients, and can be a challenge in the
diagnostic needle biopsy setting, particularly for initial diagnosis.
Due to the high incidence of prostate cancer, it is important to
recognize that hormone exposure related changes may be seen
within prostatic adenocarcinoma in cirrhotic patients.
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